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OBJECTIVE To determine the feasibility, safety and efficacy of bilevel positive airway ventilation (BiPAP)
in the treatment of severe pulmonary edema compared to high dose nitrate therapy.
BACKGROUND Although noninvasive ventilation is increasingly used in the treatment of pulmonary edema,
its efficacy has not been compared prospectively with newer treatment modalities.
METHODS We enrolled 40 consecutive patients with severe pulmonary edema (oxygen saturation ,90%
on room air prior to treatment). All patients received oxygen at a rate of 10 liter/min,
intravenous (IV) furosemide 80 mg and IV morphine 3 mg. Thereafter patients were
randomly allocated to receive 1) repeated boluses of IV isosorbide-dinitrate (ISDN) 4 mg
every 4 min (n 5 20), and 2) BiPAP ventilation and standard dose nitrate therapy (n 5 20).
Treatment was administered until oxygen saturation increased above 96% or systolic blood
pressure decreased to below 110 mm Hg or by more than 30%. Patients whose conditions
deteriorated despite therapy were intubated and mechanically ventilated. All treatment was
delivered by mobile intensive care units prior to hospital arrival.
RESULTS Patients treated by BiPAP had significantly more adverse events. Two BiPAP treated patients
died versus zero in the high dose ISDN group. Sixteen BiPAP treated patients (80%) required
intubation and mechanical ventilation compared to four (20%) in the high dose ISDN group
(p 5 0.0004). Myocardial infarction (MI) occurred in 11 (55%) and 2 (10%) patients,
respectively (p 5 0.006). The combined primary end point (death, mechanical ventilation or
MI) was observed in 17 (85%) versus 5 (25%) patients, respectively (p 5 0.0003). After 1 h
of treatment, oxygen saturation increased to 96 6 4% in the high dose ISDN group as
compared to 89 6 7% in the BiPAP group (p 5 0.017). Due to the significant deterioration
observed in patients enrolled in the BiPAP arm, the study was prematurely terminated by the
safety committee.
CONCLUSIONS High dose ISDN is safer and better than BiPAP ventilation combined with conventional therapy
in patients with severe pulmonary edema. (J Am Coll Cardiol 2000;36:832–7) © 2000 by the
American College of Cardiology
Continuous positive airway ventilation (CPAP) and bilevel
positive airway ventilation (BiPAP) are being increasingly
used in the treatment of acute respiratory failure and
pulmonary edema (1). However, to date and to our knowl-
edge, no large randomized trials have compared this treat-
ment with other treatment modalities. We have recently
demonstrated (2) that the use of intravenous (IV) high dose
isosorbide-dinitrate (ISDN) in the treatment of severe
pulmonary edema improves control of respiratory failure,
and reduces the need for mechanical ventilation and the rate
of myocardial infarction (MI). Since the two treatment
strategies are commonly used in our institution as well as
other emergency departments in Israel, we have undertaken
a study in which Bi-PAP ventilation combined with con-
ventional treatment was compared to high dose ISDN in
patients with severe pulmonary edema.
Ethical considerations dictated the different ISDN dose
in the BiPAP and control group. Patients in the BiPAP arm
were treated by BiPAP ventilation and continuous IV
ISDN. High dose IV ISDN was not coadministered with
BiPAP ventilation due to concerns about a possible hypo-
tensive effect of such treatment combination. The use of
standard-dose continuous IV ISDN as a single treatment
method was considered unethical by the hospital review
board due to the results of our previous study (2). Therefore,
we compared in a prospective randomized study the efficacy
and safety of BiPAP ventilation versus IV high dose nitrate
therapy in patients with severe pulmonary edema.
METHODS
Between January and June 1999, 40 consecutive patients
with severe pulmonary edema were recruited for the present
study. The study protocol was approved by the hospital and
national ethical review board. Severe pulmonary edema was
defined as symptoms and signs of pulmonary edema accom-
panied by oxygen saturation of ,90% measured by pulse
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oximetry upon hospital admission, prior to oxygen admin-
istration.
Exclusion criteria were as follows:
1) previous treatment with nitrates above 40 mg/d, or
mono-nitrates or long-acting tri-nitrates administered
more than twice daily or short acting tri-nitrates admin-
istered more than three times a day;
2) previous treatment with furosemide .80 mg/d;
3) hypotension (blood pressure ,110/70 mm Hg);
4) previous adverse effect of nitrates;
5) ST elevations consistent with acute MI on baseline
ECG; and
6) absence of pulmonary edema on chest radiograph ob-
tained on arrival to the emergency department.
On hospital admission, each patient was placed in sitting
position and oxygen was administered by facemask with a
rebreathing bag at a rate of 10 liter/min. An IV line was
inserted and an IV bolus of morphine 3 mg and furosemide
80 mg was administered. Informed consent was obtained.
Heart and respiratory rates, blood pressure and oximetric O2
saturation were obtained at baseline and every 3 min during
treatment. Randomization was performed by assigning con-
secutive patients to one or other of the treatment groups
according to their numerical order on a list that had been
predetermined by lot.
Patients were randomized to receive one of two treat-
ments:
1) BiPAP and conventional treatment (n 5 20): the BiPAP
was administered using a BiPAP ventilatory assist sys-
tem (Respironics), a pressure-limited device that cycles
between adjustable (up to 20 cm H2O) inspiratory and
expiratory pressures using patient flow-triggered (S)
mode. The inspiratory positive airway pressure (IPAP)
was set at 8 cm H2O initially, and the expiratory positive
airway pressure (EPAP) was set at 3 cm H2O. Supple-
mental oxygen was blended in via a mask port at a rate
of 10 liter/min. Patients were encouraged to coordinate
their breathing with the ventilator. During the trial,
IPAP was increased by 1 cm H2O every 3 to 4 min as
tolerated and up to 12 cm H2O. Subsequent EPAP was
increased by 1 cm H2O every 3 to 4 min up to 5 cm
H2O. Patients were encouraged to use BiPAP for as
long as tolerated, aiming for at least 50 min. Masks were
tightened just enough to control air leakage. Concomi-
tantly IV ISDN continuous drip was started with 10
mmol/min and increased every 5 to 10 min by 10
mmol/min.
2) High dose IV ISDN (n 5 20): IV ISDN, 4 mg-boluses,
was administered every 4 min.
The randomization and treatment of pulmonary edema
were administered by mobile intensive care unit teams in the
patient’s home or during delivery to the emergency depart-
ment. During the study period, no other drug beside
protocol study drugs was administered.
IPAP and EPAP as well as ISDN dose up-titration in
group 1 and repeated ISDN boluses in group 2 were
continued in both groups until the oxygen saturation in-
creased above 96% or systolic blood pressure dropped below
110 mm Hg systolic or 30% below baseline levels. Patients
with oxygen saturation below 80% despite therapy or
increasing dyspnea accompanied by altered neurologic status
were intubated and mechanically ventilated. Additional
morphine was administered only prior to intubation.
Primary end points were as follows: adverse events in-
cluding death, need for mechanical ventilation or MI within
24 h of hospital admission. Myocardial infarction was
defined as an increase of CK to more than twice the upper
limit of normal of our institution accompanied by an
increase in CK-MB to .6%.
Secondary end points were as follows: speed of recovery
from pulmonary edema as reflected by a decrease in pulse
and respiratory rate and increase in oxygen saturation.
Statistical analysis. Comparison between the two treat-
ment groups regarding baseline parameters, treatment and
primary end points was performed using the two-tailed
Student t test to compare continuous variables and the
Fisher exact test to compare the distribution of categorical
variables. Differences in O2 saturation, respiratory and pulse
rate changes over time were calculated by one-way analysis
of variance (ANOVA) with repeated measures. Results are
expressed as mean 6 SD. p values ,0.05 were considered
statistically significant.
RESULTS
Patient recruitment is presented in Figure 1. Baseline
characteristics of patients in both groups are presented in
Table 1. Treatment with IV ISDN, furosemide and mor-
phine is presented in Table 2. The decrease in mean arterial
blood pressure was similar in both groups (Table 3).
Primary end point (clinical outcome). Patients treated by
BiPAP ventilation had significantly more adverse events.
Two patients (10%) died in the BiPAP arm as compared to
0 (0%) in the high dose ISDN group (p 5 0.49). These
patients succumbed to complications of prolonged mechan-
ical ventilation after 2 and 10 days from treatment. Me-
chanical ventilation was required during the first hour of
treatment in 16 patients (80%) in the BiPAP group com-
pared to 4 patients (20%) in the high dose nitrate group
Abbreviations and Acronyms
ANOVA 5 analysis of variance
BiPAP 5 bilevel positive pressure ventilation
CK 5 creatine phosphokinase
CPAP 5 continuous positive airway pressure
EPAP 5 expiratory positive airway pressure
IPAP 5 inspiratory positive airway pressure
ISDN 5 isosorbide dinitrate
LVEDP 5 left ventricular end diastolic pressure
MI 5 myocardial infarction
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(p 5 0.0004). Myocardial infarction within 24 h of hospital
admission was diagnosed in 11 patients (55%) in the BiPAP
group compared to 2 patients (10%) in the high dose ISDN
group (p 5 0.006). Peak CK was 554 6 236 IU in the
BiPAP group versus 104 6 95 IU in the high dose nitrates
group (p 5 0.0001). The combined end point (death, need
for mechanical ventilation or MI within 24 h of admission)
was observed in 17 patients (85%) in the BiPAP group as
compared to 5 patients (25%) in the high dose ISDN group
(p 5 0.0003).
Secondary end points. The rate of improvement of signs
of pulmonary edema was considerably slower in the BiPAP
group compared to the high dose ISDN group (Table 3). In
the ANOVA analysis, significant time trends were noticed
in all three parameters (pulse and respiratory rate and
oxygen saturation). In addition, interaction between treat-
ment group and time trend was significant for the three
parameters, implying that the change over time in the three
treatment groups was significant. Oxygen saturation in-
creased in the BiPAP group from 80 6 6% at baseline to
89 6 7% at 50 min compared to an increase from 79 6 6%
to 96 6 4% in the high dose ISDN group (p 5 0.017, Fig.
2). The respiration rate decreased in the BiPAP group from
40 6 8 breaths/min at baseline to 36 6 11 breaths/min at
50 min compared to a decrease from 40 6 5 breaths/min to
31 6 6 breaths/min in the high dose ISDN group (p 5
0.011). Finally, the pulse rate decreased in the BiPAP group
from 128 6 10 beats/min at baseline to 121 6 18 beats/min
at 50 min compared to a decrease from 126 6 15 beats/min
to 104 6 14 beats/min in the high dose ISDN group (p 5
0.014).
Study termination. Due to the significantly high rate of
adverse events in the BiPAP-treated group, the study was
terminated in the first interim analysis by the safety com-
mittee.
DISCUSSION
The results of the present study. The results of the
present study indicate that BiPAP ventilation combined
with conventional treatment is significantly inferior to
high-dose nitrates. This is manifested by increased rate of
mechanical ventilation and MI and combined primary end
point as well as decreased control of pulmonary edema as
demonstrated by slower improvement in pulse and respira-
tion rate and oxygen saturation. As mentioned previously,
we have recently compared the use of high dose IV nitrates
to conventional treatment in patients with severe pulmonary
edema (2). Inclusion and exclusion criteria and baseline
characteristics were similar in both studies. In both studies,
high dose IV ISDN was administered in the same fashion.
However, in the control group of the present study, we have
added BiPAP ventilation to conventional treatment of
pulmonary edema. A treatment arm with only conventional
treatment was not incorporated in the present study due to
Figure 1. Recruitment algorithm of the study (six month period).
Table 1. Baseline Characteristics of Patients
High Dose
ISDN BiPAP
p
Value
No. of Patients 20 20
Age (yr) 73 6 7 72 6 6 NS
Gender distribution NS
Male 10 (50%) 9 (45%)
Female 10 (50%) 11 (55%)
Risk factors NS
Hypertension 12 (60%) 13 (65%) NS
Diabetes mellitus 11 (55%) 13 (65%) NS
Hyperlipidemia 8 (40%) 9 (45%) NS
Positive family history of IHD 8 (40%) 7 (35%) NS
Current smoker 6 (30%) 4 (20%) NS
Cardiovascular history
Prior MI 12 (60%) 14 (70%) NS
Prior PTCA 2 (10%) 3 (15%) NS
Prior CABG 5 (25%) 3 (15%) NS
Echocardiographic findings
Moderate aortic stenosis 1 (5%) 0 (0%) NS
Moderate mitral regurgitation 4 (20%) 3 (15%) NS
EF (%) 43 6 6 45 6 7 NS
BiPAP 5 bilevel positive pressure ventilation; CABG 5 coronary artery bypass
grafting; EF 5 ejection fraction; IHD 5 ischemic heart disease; ISDN 5 isosorbide
dinitrate; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty.
Table 2. Concomitant Treatment During Study Period
High Dose
ISDN BiPAP
p
Value
ISDN dose (mg) 10.8 6 5.7 3.5 6 2.5 0.0006*
Furosemide dose (mg) 85 6 28 91 6 25 0.47
Morphine dose (mg) 2.5 6 1.6 2.2 6 2.4 0.62
BiPAP pressure
IPAP (mm Hg) (2) 9.3 6 2.3
EPAP (mm Hg) (2) 4.2 6 3.1
*p is significant (p , 0.05).
BiPAP 5 bilevel positive pressure ventilation; EPAP 5 expiratory positive airway
pressure; IPAP 5 inspiratory positive airway pressure; ISDN 5 isosorbide dinitrate.
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ethical considerations, since the outcome of patients treated
by conventional treatment only was worse in our previous
study. In both studies, the outcomes of patients treated by
high dose IV ISDN were almost identical. The rate of
mechanical ventilation and MI were 20% and 10%, respec-
tively, in the present study as compared to 13% and 17% in
the previous study. However, the outcome of the patients
treated with BiPAP and conventional treatment in the
present study is significantly worse than the outcome of
patients treated with conventional treatment only in the
previous study. The rate of mechanical ventilation and MI
in BiPAP-treated patients in the present study was 80% and
55%, respectively, compared to 40% and 37% in the con-
ventional treatment arm in our previous study.
Therefore, it seems that the addition of BiPAP ventila-
tion to conventional treatment with standard-dose nitrates,
furosemide and morphine is detrimental to patients with
severe pulmonary edema.
Previous studies utilizing CPAP or BiPAP ventilation in
pulmonary edema. The use of CPAP and BiPAP ventila-
tion in the treatment of pulmonary edema has been re-
viewed recently (1,3). The results of most previous studies
showed a moderate benefit in the use of CPAP regarding
improved oxygenation, reduced need for mechanical venti-
lation and even reduced mortality. Therefore, CPAP was
endorsed by many authors for the treatment of pulmonary
edema (1,2,4). Ventilation with BiPAP has been examined
previously in a few studies (5–7). Most of these studies
recruited a small number of patients and the stratification of
baseline characteristics was not balanced, making interpre-
tation of the results difficult. However, it seems that BiPAP
ventilation, by applying a higher inspiratory pressure and
lower expiratory pressure, improves indexes of pulse and
respiration rate and oxygen saturation more than CPAP
ventilation, without any effect on the rate of mechanical
ventilation. Some authors, however, have noticed an in-
creased rate of MI (5,7).
Interpretation of the present study. Although extensively
investigated throughout the century, the exact mechanism
of pulmonary edema is still largely unknown. In most
patients, cardiogenic pulmonary edema is caused by an acute
increase of left ventricular end-diastolic pressure (LVEDP)
Table 3. Changes in Secondary End Points During Study
Time
(min)
High Dose
ISDN BiPAP
Mean arterial blood pressure (mm Hg) 0 140 6 16 133 6 26
10 130 6 17 127 6 19
20 123 6 16 120 6 14
30 119 6 16 117 6 12
40 118 6 16 116 6 12
50 118 6 19 115 6 11
Respiratory rate (breaths/min) 0 40 6 5 40 6 8
10 37 6 6 38 6 8
20 35 6 6 37 6 9
30 34 6 6 36 6 11
40 33 6 6 36 6 11
50 31 6 6 36 6 11
Pulse rate (beats/min) 0 126 6 15 128 6 10
10 122 6 14 127 6 13
20 117 6 14 124 6 15
30 112 6 13 122 6 17
40 108 6 14 121 6 18
50 104 6 14 121 6 18
Oxygen saturation (%) 0 79 6 6 80 6 6
10 86 6 5 86 6 6
20 90 6 5 88 6 7
30 93 6 4 88 6 7
40 95 6 4 88 6 7
50 96 6 4 89 6 7
ANOVA Results
Respiratory Rate Pulse Rate Oxygen saturation
F (5,34) P F (5,34) P F (5,34) P
Time 9.92 0.001* 11.67 0.001* 30.3 0.001*
F (1,38) P F (1,38) P F (1,38) P
Treatment NS NS 3.93 0.054 5.23 0.028*
F (5,34) P F (5,34) P F (5,34) P
Time X
treatment
3.54 0.011* 3.37 0.014* 3.22 0.017*
*p is significant (p , 0.05).
BiPAP 5 bilevel positive pressure ventilation; ISDN 5 isosorbide dinitrate.
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that is transmitted backward to the pulmonary veins induc-
ing fluid exudation to the pulmonary interstitium and
alveoli. This increase in LVEDP is usually the result of
acute ischemia, which decreases left ventricular diastolic
function (thereby increasing LVEDP directly) and systolic
function. It has recently been suggested (8) that pulmonary
edema is the end result of a vicious cycle in which the
decrease in cardiac output is compensated by peripheral
vasoconstriction leading to an increase in systemic vascular
resistance and afterload. However, if the peripheral vaso-
constriction is excessive, the significant increase in afterload
results in a further reduction in cardiac output leading to
more vasoconstriction and afterload increase. This vicious
cycle induces a progressive increase in LVEDP resulting in
pulmonary edema. In the present study, high dose IV ISDN
administration was more effective than BiPAP ventilation in
controlling pulmonary edema. Intravenous nitrates at both
standard and high doses induce venodilatation, therefore
reducing LVEDP directly. However, when administered at
high dose, nitrates induce significant arteriodilatation,
therefore, reducing afterload (9) and increasing cardiac
output (10). Accordingly, high dose nitrate administration
by decreasing afterload may alleviate both the decrease in
cardiac output and the increase in LVEDP. Furthermore,
this reduction in LVEDP when combined with improved
oxygenation (induced by a more rapid improvement of
pulmonary congestion) may contribute to faster abortion of
ischemia (if present) and prevention of MI.
However, BiPAP and CPAP ventilation improve control
of pulmonary edema predominantly by their effect on the
lung. These noninvasive ventilation methods improve pul-
monary compliance (11,12), reduce atelectasis and intrapul-
monary shunting and increase the functional residual capac-
ity. The BiPAP ventilation, particularly, increases tidal
volume even more than CPAP and reduces the work of
breathing (13). The effects of CPAP and BiPAP on the
cardiovascular system are controversial. Both increase in-
trathoracic pressure, which induces a decrease in preload
and afterload. However, the increased intrathoracic pressure
per se may reduce stroke volume directly. It is possible that
this would lead to an increase in LVEDP, reduce control of
pulmonary edema and increase the need for mechanical
ventilation. The reduced control of pulmonary edema and
elevated LVEDP may increase ischemia and rate of MI.
The results of the present study are in conflict with
previous studies. This might be explained by the more
severe pulmonary edema in the present cohort.
Baseline oxygen saturation of patients included in the
present study was 80% corresponding to PO2 of
,50 mm Hg while in most studies demonstrating the
efficacy of CPAP and BiPAP ventilation, patients included
had much higher baseline PO2. Furthermore, in both the
present study and our previous one (2), the treatment of
pulmonary edema was administered by mobile intensive care
unit teams at the patient’s home or in the ambulance.
Accordingly, it is possible that the conditions of some of the
patients treated in previous studies would have deteriorated
significantly during the initial treatment and transportation,
and they would have required intubation and mechanical
ventilation prior to arrival to the emergency department.
This would introduce a further bias, causing a recruitment
drift toward milder cases in the previous studies, explaining
the lower baseline oxygen saturation in the present study.
Therefore, it is possible that noninvasive ventilation is
effective only in patients with mild-to-moderate pulmonary
edema. In such patients, the improved oxygenation achieved
is probably sufficient to initiate a gradual improvement in
the patient’s clinical condition that is later enhanced
throughout the gradual build-up of medical therapy.
However, in patients with severe pulmonary edema, the
decrease in cardiac output and increase in LVEDP are
probably more pronounced at baseline. In such patients,
further decrease in stroke volume induced by increased
intrathoracic pressure might be detrimental, resulting in
patient condition deterioration toward respiratory failure,
mechanical ventilation, ischemia and MI.
Therefore, the results of both the present study and our
previous one (2) substantiate the notion that the target of
treatment in severe pulmonary edema should be decreasing
the excessive vasoconstriction and afterload, thereby im-
proving cardiac output. This vasodilatation could be
achieved by high dose nitrates and perhaps in the future
with enthotelin antagonists. These treatment modalities
should be preferred over the nonspecific and possibly
harmful attempts to improve oxygenation by noninvasive
positive pressure ventilation.
Reprint requests and correspondence: Gad Cotter MD, The
Cardiology Institute, Assaf-Harofeh Medical Center, 70300,
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Figure 2. Changes in oxygen saturation during study period comparing the
high dose IV ISDN Group and the BiPAP group.
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